{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["50(4)"],"submitter":["Kappel-Latif S"],"funding":["Medical University of Vienna"],"pubmed_abstract":["<h4>Background</h4>In operable esophageal cancer patients, neoadjuvant therapy benefits only those who respond to the treatment. The • Pancho trial represents the first prospective randomized trial evaluating the relevance of the mark53 status for predicting the effect of two different neoadjuvant chemotherapies.<h4>Method</h4>Biomarker analysis was conducted using the mark53 analysis. Calculation of patient number needed was based on a 60% rate of marker positivity, deduced from the results of a phase II pilot study.<h4>Results</h4>From 2007-2012, the • Pancho trial recruited 235 patients with operable esophageal cancer in Austria. A total of 181 patients were eligible and could be subjected to mark53 analysis and randomization. After randomizing 74 patients, the overall <i>TP53</i> mutat"],"journal":["European surgery : ACA : Acta chirurgica Austriaca"],"pagination":["160-166"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6290852"],"repository":["biostudies-literature"],"pubmed_title":["• Pancho trial (p53-adapted neoadjuvant chemotherapy for resectable esophageal cancer) completed-mutation rate of the marker higher than expected."],"pmcid":["PMC6290852"],"pubmed_authors":["Pancho trialists and for the Medical University of Vienna p53research group","Brugger S","Stiglbauer W","Dablander E","Neumann HJ","Silye R","Denk H","Odelga V","Kain R","Pantucek F","Klimpfinger M","Lichtenegger K","Eisterer W","Kuzmits R","Sporn S","Kappel-Latif S","Prager G","Hofler G","Merz P","Weiß H","Knauer M","Teleky B","Uffmann M","Bernhart M","Kerjaschki D","Aberer B","Trabe W","Feichtinger J","Chott A","Schermann M","Beer F","Bonner E","Tomaselli F","Berger F","Beck E","Sagaster V","Ofner D","Brammen L","Karner J","Schoppmann SF","Leitner G","Eberl T","Bergmann N","Naude S","Kandioler D","Fugger R","Tamandl D","Moinfar F","Sedivy R","Klepetko W","Thur M","Guggenberger W","Eberhard N","Kessler T","Veit D","Smetana U","Sega W","Hold M","Mostegel M","Heinke B","Weeber K","Riegler M","Veit T","Haid A","Pourebrahim H","Ammann K","Riegler V","Viragos-Toth I","Tinchon C","Hohlagschwandtner M","Kadlecek V","Zwrtek R","Rogatsch H","Tschmelitsch J","Rapp N","Brunner A","Galowitsch S","Mittlbock M","Braun O","Westerhoff M","Haller J","Glaser K","Danko G","Lang A","Offner F","Neuhold N","Dietze O","Gogl H","Pluschnig U","Essenther M","Nader A","Aigner C","Sandurkov C","Gotzinger P","Schoppmann S","Frcena E","Hejna M","Ba-Ssalamah A","Muhlbacher F","Rabl H","Kuhrer I","Gnant M","Friedl J","Hudec M","Mikuz G","Grunberger T","Wustinger C","Kristandl E","Keil F","Maderdonner M","Hobling W","Muhlmann G","Langle F","Kees-Belyus M","Niederle B","Wenzl E","Muhlmann J","Braun OM","Wrba F","Heinz G","Pober M","Wolf B","Lercher-Lueger M","Bichler C","Kainz H","Adolf W","Fortelny R","Kitzwogerer M","Strasser-Weipl K","Schenk T","Metz S","Osterreicher C","Roka S","Roka R","Kosak D","Kastner U","Jakesz R","Werba G","Hartmann B","Zitt M","Thalhammer S","Maier H","Freibauer C","Zacherl J"],"additional_accession":[]},"is_claimable":false,"name":"• Pancho trial (p53-adapted neoadjuvant chemotherapy for resectable esophageal cancer) completed-mutation rate of the marker higher than expected.","description":"<h4>Background</h4>In operable esophageal cancer patients, neoadjuvant therapy benefits only those who respond to the treatment. The • Pancho trial represents the first prospective randomized trial evaluating the relevance of the mark53 status for predicting the effect of two different neoadjuvant chemotherapies.<h4>Method</h4>Biomarker analysis was conducted using the mark53 analysis. Calculation of patient number needed was based on a 60% rate of marker positivity, deduced from the results of a phase II pilot study.<h4>Results</h4>From 2007-2012, the • Pancho trial recruited 235 patients with operable esophageal cancer in Austria. A total of 181 patients were eligible and could be subjected to mark53 analysis and randomization. After randomizing 74 patients, the overall <i>TP53</i> mutat","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018","modification":"2025-04-04T22:53:17.677Z","creation":"2019-03-27T00:12:25Z"},"accession":"S-EPMC6290852","cross_references":{"pubmed":["30559831"],"doi":["10.1007/s10353-018-0527-z"]}}